A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody
- 199 Downloads
Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the prognosis. We report a case of a 28-year-old patient with plasma-cell type, human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative MCD who responded to treatment with chemotherapy and the anti-CD20 monoclonal antibody, rituximab. Anti-CD20 therapy could be an interesting adjunctive treatment in MCD.
KeywordsAnti-CD20 monoclonal antibody Multicentric Castleman's disease Secondary amyloidosis
The authors are grateful to Ms. Lorna Saint Ange for editing.
- 2.Flendrig J, Schillings PHM (1969) Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 12:119Google Scholar
- 23.Van Eygen K, Zachee P, Maertens J, Vandenberghe P, Demuynck H, Verhoef G, Boogaerts A (1996) Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival. Blood 88(1):591aGoogle Scholar